Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nitinol carotid stent enters trials:

This article was originally published in Clinica

Executive Summary

US endovascular device start-up EndoTex Interventional Systems plans to begin a 45-patient, Phase I study of its nitinol carotid stent now that it has FDA approval to begin enrolling patients. The Cupertino, California-based company's NexStent device has been implanted in patients in Argentina and Chile under investigational use with no complications. The company, which counts Guidant and US Surgical (now Tyco) among its investors, has been developing nitinol-based vascular products for four years. EndoTex also has an agreement to develop products for repairing aortic aneurysms and AV fistulas with US Surgical.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT073110

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel